Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease

Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease

<p>Abstract</p> <p>Background</p> <p>A large proportion of patients with autosomal dominant polycystic kidney disease (ADPKD) suffers from polycystic liver disease. Symptoms arise when liver volume increases. The somatostatin analogue lanreotide has proven to reduce liv...

Full description

Bibliographic Details
Main Authors: Gevers Tom JG, Chrispijn Melissa, Wetzels Jack FM, Drenth Joost PH
Format: Article
Language:English
Published: BMC 2012-04-01
Series:BMC Nephrology
Subjects:
ADPKD
Urinary biomarkers
Polycystic liver disease
Lanreotide
Online Access:http://www.biomedcentral.com/1471-2369/13/17

Similar Items

Similar Items